MONTREAL, Feb. 26 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that Chief Financial Officer, L. Derek Lindsay, will be leaving the Company on April 4, 2008. Effective April 7, 2008, Ginette Gagne will take over the role of Chief Financial Officer at CryoCath. Mr. Lindsay has agreed to stay on in the role of Chief Financial Officer to ensure a smooth transition.
“Since joining CryoCath, Derek has been actively involved in significant change and we thank him for his contributions to the Company’s development and wish him well for the future,” said Jan Keltjens, President and Chief Executive Officer of CryoCath. “I am very pleased to announce the appointment of Ginette Gagne to the position of Chief Financial Officer at CryoCath. Her extensive experience building and running world-class financial organizations, combined with her hands-on experience in the global medical device business, will support CryoCath in achieving our ambitious growth strategy.”
Over the past 19 years, Ginette has developed an impressive career track record through leadership positions in various corporations with progressive senior roles and responsibilities. She joins CryoCath from Boston Scientific Corporation, where she most recently served as Vice President Finance of Europe. In this capacity, she was responsible for managing a team of more than 150 people in 30 countries and played a key role in transitioning their business from a highly centralized model to a country focused model. Before this assignment she was the Vice President, Finance of Boston Scientific Inter Continental. Prior to her eight years with Boston Scientific, Ginette held financial leadership roles at Fisher Scientific International, Fisher France OSI S.A. and Fisher Scientific Canada. She began her career with Northern Telecom Ltd.
About CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes “forward-looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.
CONTACT: visit our website at www.cryocath.com, or contact: Michael Moore,
Investor Relations, Phone: (416) 815-0700 ext. 241, Fax: (416) 815-0080,
E-mail: mmoore@equicomgroup.com
